Koichi Aso

Randomized, controlled study on adjuvant immunochemotherapy with PSK® in curatively resected colorectal cancer

A randomized, controlled trial of adjuvant immunochemotherapy with PSK®(Kureha Chemical Industry Co., Tokyo, Japan) in curatively resected colorectal cancer was studied in 35 institutions in the Kanagawa prefecture. From March 1985 to February 1987, 462 patients were registered. Four hundred forty-eight of those patients (97.0 percent) satisfied the eligibility criteria. The control group received mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) administration for over six months. The PSK®group received PSK®orally for over three years, in addition to mitomycin C and 5-FU as in the control group. At the end of February 1990, the median follow-up time for this study was four years (range, three to five years). The disease-free survival curve and the survival curve of the PSK®group were better than those of the control group, and differences between the two groups were statistically significant (disease-free survival,P=0.013; survival,P=0.013). These results indicate that adjuvant immunochemotherapy with PSK®was beneficial for curatively resected colorectal cancer.

THE MODE OF SPREAD OF PANCREAS CANCER ON MACROSCOPIC AND MICROSCOPIC INVESTIGATION AT OPERATION AND AUTOPSY

北里大学外科で昭和46年7月より昭和60年12月までに経験した膵癌 (Ductcell carcinoma) 手術症例80例, 剖検症例24例につき膵癌の進展形式を検討し以下の結果を得た.1) 切除例においても, 膵被膜浸潤, 膵後方剥離面への癌侵襲陽性のものが多かった.2) 切除剖検例6例の検討では, 全例局在再発, 肝転移がみられ, 腹膜播種も5例にみられた.3) 非切除例の検討では非切除の因子として門脈系浸潤, 動脈系への浸潤, 膵後方浸潤が多かった.また肝転移, 腹膜播種が非切除の因子となったものもみられた.これらの検討をもとに昭和61年1月より積極的に門脈合併切除を伴う拡大手術を行い膵頭部癌の切除率が26.3%より50.0%と向上した.